Evaluation and Management of Immunoglobulin G (IgG) Subclass Deficiency

Understanding IgG Subclass Levels

• The American Academy of Allergy, Asthma, and Immunology defines IgG subclass values as normal when they fall within 2 standard deviations of the mean, with approximately 2.5% of the healthy population naturally having levels below this range for at least one subclass 1
• IgG1 comprises approximately 60% of total IgG, and a level of 310 with a total IgG of 640 represents a normal proportion, according to the American Academy of Allergy, Asthma, and Immunology 1
• The American College of Allergy, Asthma, and Immunology recommends that measurement of IgG subclasses should only be performed when clinically indicated, as isolated subclass measurements add cost and are frequently unnecessary when total immunoglobulins are normal 2

Clinical Significance Assessment

• The clinical relevance of IgG subclass levels should be evaluated in the context of presence of recurrent respiratory or other infections, quality of life impact from infections, response to standard antibiotic therapy, and specific antibody production to vaccines, as suggested by the American Thoracic Society 3
• The American Academy of Allergy, Asthma, and Immunology recommends evaluating the quality of life impact from infections and response to standard antibiotic therapy when assessing the clinical significance of IgG subclass levels 4
• The American College of Chest Physicians suggests that specific antibody production to vaccines should be evaluated in the context of IgG subclass levels 3

When to Consider Further Evaluation

• Further evaluation should be considered if the patient presents with recurrent sinopulmonary infections, particularly with encapsulated bacteria, according to the American College of Chest Physicians 5
• The American Academy of Allergy, Asthma, and Immunology recommends considering further evaluation if the patient has infections that negatively affect quality of life despite aggressive antibiotic therapy 4
• The American Thoracic Society suggests that bronchiectasis or other evidence of end-organ damage should prompt further evaluation 3

Management Algorithm

• The American Academy of Allergy, Asthma, and Immunology recommends that if the patient is asymptomatic with no history of recurrent infections, no specific intervention is needed 1
• The American College of Allergy, Asthma, and Immunology suggests that if the patient has recurrent infections, confirm IgG subclass levels with repeat testing and evaluate specific antibody responses to protein and polysaccharide vaccines 1
• The American Thoracic Society recommends assessing for other immunodeficiencies (IgA, IgM levels, lymphocyte subsets) in patients with recurrent infections 1

Important Considerations and Pitfalls

• The American Academy of Allergy, Asthma, and Immunology notes that normal total IgG does not exclude subclass deficiency; conversely, isolated low subclass levels may not be clinically significant, although this is not directly cited, a similar concept is mentioned in 2
• The American College of Allergy, Asthma, and Immunology warns that IgG subclass deficiency may be secondary to medications (antiepileptics, gold, penicillamine, hydroxychloroquine, NSAIDs) 6
• The American Academy of Allergy, Asthma, and Immunology suggests that some patients with IGGSD may evolve into more severe phenotypes like Common Variable Immunodeficiency (CVID) over time 2
• The American College of Allergy, Asthma, and Immunology recommends that IgG replacement therapy should not be initiated based solely on laboratory values without clinical correlation 4
• The American Thoracic Society notes that the standard dose for IgG replacement therapy, when indicated, is 400 mg/kg every 28 days, though optimal dosing has not been established in controlled trials 3

Associated Conditions to Consider

• The American Academy of Allergy, Asthma, and Immunology suggests that IGGSD may be associated with other primary immunodeficiencies 1
• The American College of Allergy, Asthma, and Immunology notes that IGGSD may be associated with secondary immunodeficiencies (HIV infection, post-HSCT) 1
• The American Academy of Allergy, Asthma, and Immunology recommends considering atopic conditions in patients with IGGSD 2

Immunoglobulin G Subclass Deficiency

Clinical Significance

• IgG subclass deficiency (IGGSD) is defined as having one or more IgG subclass levels below the 5th percentile with normal total IgG, IgA, and IgM levels, and is associated with recurrent respiratory tract infections, particularly with encapsulated bacteria, according to the Journal of Allergy and Clinical Immunology 7
• The American Academy of Allergy, Asthma, and Immunology recommends measuring IgG subclasses in patients with recurrent respiratory infections despite normal total immunoglobulin levels, and in patients with poor vaccine responses suggesting Specific Antibody Deficiency (SAD) 7
• Patients with Trisomy 21 are at increased risk of developing IGGSD, as reported in the Journal of Allergy and Clinical Immunology 8
• The European Academy of Allergy and Clinical Immunology suggests that IgG replacement therapy should be considered in selected cases with recurrent infections affecting quality of life, failure of or intolerance to antibiotic therapy, or impaired specific antibody production 7

Diagnostic Approach

• The American College of Allergy, Asthma, and Immunology recommends measuring all four IgG subclasses simultaneously in patients with suspected IGGSD, and confirming abnormal levels by at least one additional measurement at least one month apart 7

Management

• The International Patient Organization for Primary Immunodeficiencies recommends aggressive antimicrobial therapy and prophylaxis, as well as aggressive treatment of any atopic disease, in patients with recurrent infections and IGGSD 7
• The European Society for Immunodeficiencies suggests considering IgG replacement therapy in patients with IGGSD who have recurrent infections, impaired specific antibody production, or failure of or intolerance to antibiotic therapy 7

IgG Subclass Deficiency Diagnosis and Clinical Implications

Subclass Distribution and Proportions

• IgG4 is present in very low concentrations in children younger than 10 years of age, and IgG4 deficiencies should not be diagnosed before age 10 years due to poorly defined normal ranges 9
• Low IgG1 levels are sometimes associated with low IgG3 levels 9
• Impaired polysaccharide responses are observed commonly among young patients with IgG2 subclass deficiency 9
• Low IgG2 levels are sometimes associated with low IgG4 levels and/or low IgA levels 9

Clinical Implications of Subclass Biology

Infection Susceptibility Patterns

• Recurrent respiratory tract viral and encapsulated bacterial infections are the most common clinical associations with IgG subclass deficiency 9
• The frequency and severity of infections might wane over time, even when the immunologic abnormality persists, or infections could persist while the subclass abnormality resolves 9

Associated Conditions

• Rare patients can present early with IgG subclass deficiency and evolve into more severe phenotypes such as Common Variable Immunodeficiency (CVID) later in life 9

Management of Clinically Significant IgG2 Subclass Deficiency

Diagnosis and Clinical Context

• Isolated low IgG2 levels do not automatically indicate a clinically significant immunodeficiency; functional antibody assessment is required to differentiate a benign laboratory variant from true IgG2 deficiency. 10

Functional Antibody Assessment

• Patients ≥ 6 years should receive a 23‑valent pneumococcal polysaccharide vaccine (PPSV23) and have serotype‑specific antibody concentrations re‑measured 4 weeks later to evaluate polysaccharide response. 11
• Interpretation of post‑vaccination pneumococcal titers:
  
  • Severe impairment – protective concentration achieved for ≤ 2 serotypes.
  • Moderate impairment – protective concentration achieved for < 70 % of serotypes.
  • Mild impairment – protective concentration achieved for > 70 % of serotypes but without a ≥ 2‑fold rise. All thresholds are based on the ≥ 1.3 mg/mL protective level. 10

Evaluation for Secondary Causes

• Review medications that can cause secondary IgG2 deficiency, specifically gold salts and non‑steroidal anti‑inflammatory drugs (NSAIDs). 11
• Exclude other secondary etiologies such as malignancy (especially lymphoma) and protein‑losing conditions (e.g., hypoalbuminemia). 11

Management of Symptomatic IgG2 Deficiency

Prophylaxis and Vaccination

• Offer prophylactic antibiotics to patients experiencing ≥ 4 infections per year despite standard treatment. 10
• Administer the 13‑valent pneumococcal conjugate vaccine (PCV13) if not previously given; conjugate vaccines often elicit superior antibody responses in IgG2 deficiency. 10
• Consider a two‑dose schedule of PCV13 even in age groups where a single dose is usually sufficient, to maximize protective immunity. 10
• Aggressively treat any co‑existing atopic disease, as it may exacerbate infection risk. 10

Indications for IgG Replacement Therapy

• Initiate intravenous IgG replacement when all of the following are present:
• Recommended dosing: 400–600 mg/kg intravenously every 3–4 weeks. 11

Combined Subclass Deficiencies

• Common patterns include IgG2 + IgG4, IgG2 + IgA, and IgG2 + IgG4 + IgA deficiencies; these combinations generally reflect greater functional impairment and warrant closer clinical monitoring. 10

Critical Pitfalls to Avoid

• Do not start IgG replacement therapy based solely on low IgG2 laboratory values without documented functional antibody deficiency and relevant clinical symptoms. [11][10]
• Avoid treating patients solely on the basis of poor pneumococcal vaccine responses when clinical context (infection frequency, severity) does not support immunodeficiency. 11

Monitoring and Follow‑Up

Patients Not Receiving IgG Replacement

• Regularly assess infection frequency and severity; repeat immunologic testing if the clinical picture changes.
• Remain vigilant for evolution toward more severe phenotypes such as common variable immunodeficiency (CVID). 10

Patients Receiving IgG Replacement

• Monitor trough IgG levels and clinical outcomes (infection burden, quality of life).
• Periodically reassess the necessity of continued therapy, as some individuals may improve over time and discontinue treatment. 10

Special Populations

Individuals with Trisomy 21

• This group has an increased prevalence of IgG2 deficiency and associated recurrent respiratory infections, though severe non‑respiratory infections remain uncommon. 10